THBD and Sepsis: Using an in vitro study involving human neutrophil and platelet cultures, we have reported that recombinant human soluble thrombomodulin (rTM) suppresses lipopolysaccharide (LPS)-induced NET formation [14], and we have hypothesized that by suppressing NET formation, TM prevents organ damage during sepsis onset, thereby improving survival rates.